Responses
Clinical and epidemiological research
Extended report
Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
Compose a Response to This Article
Other responses
No responses have been published for this article.